Adiponectin Testing Market Opportunity Assessment and Forecast up to 2027

Global Adiponectin Testing Market: Snapshot Adioponectin has shown substantial clinical potential as an adipocyte-derived protein in the pathophysiology of the metabolic diseases and coronary artery disease. Higher levels of circulating adiponectin is linked with high risk of adverse cardiovascular events, pre-diabetes, and metabolic syndrome. Read Report Overview - https://www.transparencymarketresearch.com/adiponectin-testingmarket.html Several studies done on animal models have highlighted these findings, a key evolutionary factor for the adiponectin testing market. The health care industry has also focused form benefitting from the testing on animals where anti-inflammatory, antiatherogenic, cardiomyocyte-protective, and insulin-sensitizing properties of the hormone is utilized. Over the recent decade, substantial efforts have been made in exploring the use of adiponectin testing as a potential biomarker in insulin sensitivity and obesity in human patients. Still, the test isn’t considered as a key determinant in conclusively identifying metabolic disease risks in patients. However, in recent years, the testing has growing in application for livestock. The key application areas of the adiponectin testing are for diagnostics and research. Methods used comprise enzyme linked immunosorbent assay (ELISA) and enzyme immunoassay kits. Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php? flag=B&rep_id=74344 Global Adiponectin Testing Market: Growth Dynamics The drive for the adiponectin testing market stems from the growing potential of adipose-derived products as a drug target to treat as well as prevent cardiometabolic diseases. New prospects have emerged in the market from growing body of research on understanding the pathophysiology of metabolic syndrome. The syndrome has evoked intense concern across worldwide healthcare systems. The marked mortality of diseases caused by this syndrome, such as non-alcoholic fatty liver disease (NAFLD), cardiovascular disease (CVD), and type 2 diabetes, has augmented the scope of the adiponectin testing market. Drug makers in recent years have been focusing on new drug targets for insulin resistance (IR)-related metabolic disorders. This has also propelled industry interest in adiponectin testing. On the other hand, the growing demand for population for the diagnosis of hypoadiponectinemia has bolstered the prospects of the adiponectin testing market. Growing epidemic of obese population of all ages has also been fueling clinical studies on adiponectin levels in the body. Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php? flag=CR&rep_id=74344 Global Adiponectin Testing Market: Notable Developments The advent of functional food ingredients that claim to improve adipocyte health and adiponectin metabolism has expanded the avenue for market players. Over the years, studies that aims at the metaanalysis of the hormone as a biomarker for the detection of metabolic syndrome has gained steam,

Turn static files into dynamic content formats.

Create a flipbook